This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 16

Combination Therapy of Vertex Cystic Fibrosis Drugs Hits Big Mark

By Adam Feuerstein

Combination therapy of two Vertex Pharmaceuticals drugs hit a big mark in the treatment of cystic fibrosis.

10:02AM 06/24/14

Biotech Selloff Causes Nasdaq to Drop Over 2%

By Adam Feuerstein

The volatile biotech sector is experiencing extreme selling on Friday, pushing the NASDAQ down over 2%. The selling has gained in volume and speed as no one wants to be the last trader standing.

02:02PM 04/04/14

Biotech's Next Big Thing: Fall Trials

By Adam Feuerstein

Its been a busy summer for biotech, but the coming weeks will heat up with trials from Biodel, Achillon and Coronado, says Adam Feuerstein, Sr. Columnist at TheStreet.

05:00AM 08/23/13

Biotech's Next Big Thing: Earnings

By Adam Feuerstein

It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.

12:38PM 08/01/13

Perrigo Elan Play Pure Tax Ploy

By Adam Feuerstein

The only part of Perrigo actually moving to Ireland post the Elan deal is its bank account, says Adam Feuerstein, Sr. Columnist at TheStreet.

12:15PM 07/29/13

Biotech's Next Big Thing: Alnylam

By Adam Feuerstein

Alnylam Pharmaceuticals upcoming meeting is the next big thing in biotech, says TheStreet Sr. columnist Adam Feuerstein.

08:34AM 07/01/13

Biotech's Next Big Thing: Biogen

By Adam Feuerstein

Biogen Idec's earnings will be the next big thing in biotech says TheStreet Sr. Columnist Adam Feuerstein.

08:20AM 06/21/13

Biotech's Next Big Thing -- ASCO II

By Adam Feuerstein

TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.

02:09PM 05/16/13

Biotech's Next Big Thing: ASCO

By Adam Feuerstein

TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.

09:39AM 05/09/13

Biotech's Next Big Thing: Aveo

By Adam Feuerstein

TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.

09:34AM 04/25/13

« Back
Page 1 of 16

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs